Effect of recombinant human CD26/DPPIV protein or Sitagliptin (DPPIV enzyme inhibitor) on CD3 T cells at day 2 after in vitro cell culture
To examine the impacts of recombinant human CD26/DPPIV protein and Sitagliptin on donor T-cell activation Overall design: we performed in vitro cell culture assays on T cells selected from PBMCs of healthy donor by adding PHA-L (1.25 µg/mL, control group), PHA-L + recombinant human CD26/DPPIV protein (1000 ng/mL, sCD26 group) or PHA-L + Sitagliptin (DPPIV enzyme inhibitor, 200 µg/mL, Sitagliptin group) for 2 days